Skip to main content
Erschienen in: Digestive Diseases and Sciences 10/2013

01.10.2013 | Original Article

Pain and Opioid Use in Chronic Liver Disease

verfasst von: Shari S. Rogal, Daniel Winger, Klaus Bielefeldt, Eva Szigethy

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Pain is common in patients with liver disease, difficult to treat, and poorly understood.

Aims

The aim of this study was to determine factors associated with pain and prescription opioid use in a large cohort of patients with confirmed chronic liver disease.

Methods

This was a retrospective cohort study of consecutive patients with chronic liver disease visiting a tertiary-care hepatology clinic. Pain was determined by self-report and rated numerically from 0 to 10. Symptoms of mood and sleep disorders and emotional distress were based on a symptom checklist. Etiology and stage of liver disease and use of prescribed opioids were abstracted from the electronic medical record. Logistic regression was used to establish factors associated with pain and prescription opioid use.

Results

Among 1,286 patients with chronic liver disease, 34 % had pain and 25 % used opioids. The strongest predictor of pain in multivariate modeling was emotional distress (OR 3.66, 95 % CI 2.40–5.64), followed by non-white race (OR 1.87, 95 % CI 1.24–2.79), mood symptoms (OR 1.47, 95 % CI 1.04–2.07), sleep disturbance/fatigue (OR 1.70, 95 % CI 1.24–2.32), and advanced liver disease (Child class B: OR 1.73, 95 % CI 1.15–2.60; Child class C: OR 2.78, 95 % CI 1.49–5.24) compared to no cirrhosis. Emotional distress, mood-related symptoms, and advanced liver disease were also significant predictors of prescription opioid use, as were age, nicotine use, and etiology of liver disease.

Conclusions

This large cohort study demonstrates the high prevalence of pain and opioid use in chronic liver disease. While disease variables contribute to pain, psychological symptoms were most strongly associated with pain and opioid use, providing rationale and target for therapeutic interventions.
Literatur
1.
Zurück zum Zitat Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120:170–178.PubMedCrossRef Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120:170–178.PubMedCrossRef
7.
Zurück zum Zitat Riley TR III, Koch K. Characteristics of upper abdominal pain in those with chronic liver disease. Dig Dis Sci. 2003;48:1914–1918.PubMedCrossRef Riley TR III, Koch K. Characteristics of upper abdominal pain in those with chronic liver disease. Dig Dis Sci. 2003;48:1914–1918.PubMedCrossRef
8.
9.
Zurück zum Zitat Alok R, Das SK, Agarwal GG, Salwahan L, Srivastava R. Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol. 2011;29:S70–S72.PubMed Alok R, Das SK, Agarwal GG, Salwahan L, Srivastava R. Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol. 2011;29:S70–S72.PubMed
11.
Zurück zum Zitat Ewusi-Mensah I, Saunders JB, Wodak AD, Murray RM, Williams R. Psychiatric morbidity in patients with alcoholic liver disease. Br Med J (Clin Res Ed). 1983;287:1417–1419.CrossRef Ewusi-Mensah I, Saunders JB, Wodak AD, Murray RM, Williams R. Psychiatric morbidity in patients with alcoholic liver disease. Br Med J (Clin Res Ed). 1983;287:1417–1419.CrossRef
12.
Zurück zum Zitat Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284.PubMedCrossRef Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284.PubMedCrossRef
13.
Zurück zum Zitat Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol. 1994;89:1840–1843.PubMed Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol. 1994;89:1840–1843.PubMed
14.
Zurück zum Zitat McKenna O, Cunningham C, Blake C. Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey. BMC Public Health. 2009;9:232.CrossRef McKenna O, Cunningham C, Blake C. Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey. BMC Public Health. 2009;9:232.CrossRef
15.
Zurück zum Zitat daCosta DiBonaventura M, Yuan Y, Wagner J, L’Italien G, Lescrauwaet B, Langley P. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol. 2012;24:869–877. daCosta DiBonaventura M, Yuan Y, Wagner J, L’Italien G, Lescrauwaet B, Langley P. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol. 2012;24:869–877.
16.
Zurück zum Zitat Louie K, St Laurent S, Forssen U, Mundy L, Pimenta J. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012;12:86.PubMedCrossRef Louie K, St Laurent S, Forssen U, Mundy L, Pimenta J. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis. 2012;12:86.PubMedCrossRef
18.
Zurück zum Zitat Liu G, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15:S65–S71.PubMedCrossRef Liu G, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15:S65–S71.PubMedCrossRef
24.
27.
Zurück zum Zitat Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355–1360. doi:10.1111/j.1572-0241.1999.01087.x.PubMed Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355–1360. doi:10.​1111/​j.​1572-0241.​1999.​01087.​x.PubMed
29.
Zurück zum Zitat Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94:38–47. doi:10.1016/j.drugalcdep.2007.09.018. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94:38–47. doi:10.​1016/​j.​drugalcdep.​2007.​09.​018.
30.
Zurück zum Zitat Sabin JA, Greenwald AG. The influence of implicit bias on treatment recommendations for 4 common pediatric conditions: pain, urinary tract infection, attention deficit hyperactivity disorder, and asthma. Am J Public Health. 2012;102:988–995. doi:10.2105/AJPH.2011.300621.PubMedCrossRef Sabin JA, Greenwald AG. The influence of implicit bias on treatment recommendations for 4 common pediatric conditions: pain, urinary tract infection, attention deficit hyperactivity disorder, and asthma. Am J Public Health. 2012;102:988–995. doi:10.​2105/​AJPH.​2011.​300621.PubMedCrossRef
32.
Zurück zum Zitat Williams DR. Race, socioeconomic status, and health. The added effects of racism and discrimination. Ann NY Acad Sci. 1999;896:173–188.PubMedCrossRef Williams DR. Race, socioeconomic status, and health. The added effects of racism and discrimination. Ann NY Acad Sci. 1999;896:173–188.PubMedCrossRef
33.
Zurück zum Zitat Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440–449. doi:10.1016/j.pain.2008.04.027. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440–449. doi:10.​1016/​j.​pain.​2008.​04.​027.
35.
Zurück zum Zitat Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064; quiz e133–e134. doi:10.1016/j.cgh.2011.08.013. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064; quiz e133–e134. doi:10.​1016/​j.​cgh.​2011.​08.​013.
37.
Zurück zum Zitat Nusrat S, Yadav D, Bielefeldt K. Pain and opioid use in chronic pancreatitis. Pancreas. 2012;41:264–267. Nusrat S, Yadav D, Bielefeldt K. Pain and opioid use in chronic pancreatitis. Pancreas. 2012;41:264–267.
Metadaten
Titel
Pain and Opioid Use in Chronic Liver Disease
verfasst von
Shari S. Rogal
Daniel Winger
Klaus Bielefeldt
Eva Szigethy
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2638-5

Weitere Artikel der Ausgabe 10/2013

Digestive Diseases and Sciences 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.